Martinsried/Munich, 16 March 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at three upcoming international conferences:
- 3rd Symposium on Adoptive T Cell Therapy
Date: 17 - 18 March 2016
Location: Munich, Germany
Prof. Dolores Schendel, CEO/CSO of Medigene AG will chair the session I of the conference: "Targets for adoptive T cell therapy" on 17 March
- CANCER ADVANCE
Date: 04 - 05 April 2016
Location: Boston, MA, USA
Prof. Dolores Schendel, CEO/CSO of Medigene AG will participate on a panel discussion titled "T Cell Therapies: What's New?" on 5 April at 1:20-2:00 pm
- BIO-Europe Spring
Date: 04 - 06 March 2016
Location: Stockholm, Sweden
Dr. Dr. Olav Zilian, SVP Corporate Development of Medigene AG will participate on a panel discussion titled "Targeted cancer therapies: Break through in new treatments" on 04 April at 2:45 - 3:45 pm in room E5. Additionally, he will hold a company presentation on 06 April at 10:15 am in room E6/7
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (firstname.lastname@example.org). We will then delete your address from our distribution list.